Skip to main content

Table 1 Comparison of clinical characteristics of patients in each group

From: N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study

Characteristics Group 1
PAH
Group 2
At risk
Group 3
ILD
Group 4
Controls
Pvalue
Number (n) 15 30 19 30 N/A
Age at onset (years) 44.5 ± 12.9 51.5 ± 14.8 40.3 ± 15.6 40.6 ± 13.2 0.015a
Age at study (years) 63.3 ± 10.5 66.0 ± 11.8 51.1 ± 12.7 48.7 ± 10.1 < 0.0001b
Disease duration (years) 18.8 ± 13.5 14.5 ± 10.4 10.8 ± 7.9 7.8 ± 7.2 0.003c
Female, n (%) 12 (80) 25 (83) 14 (74) 30 (100) 0.04
Male, n (%) 3 (20) 5 (17) 5 (26) 0  
Limited (n) 13 28 6 23 < 0.0001d
Diffuse (n) 2 2 13 7  
ANA, n 14 27 17 30 0.43
Anti-Scl70, n 1 3 10 5 0.001e
Anti-cent, n 7 21 0 16 < 0.0001f
WHO FC      
-I 0 5 0 25 N/A
-II 2 11 12 5  
-III 11 14 6 0  
-IV 2 0 1 0  
  1. Dis. Duration, disease duration; PAH, pulmonary arterial hypertension; WHO FC, World Health Organisation Functional Class; ANA, anti-nuclear antibody; anti-Scl70, anti- topoisomerase-1 antibody; anti-cent, anti-centromere antibody. aOlder age at SSc onset in at-risk group versus other groups. bOlder age at time of study in PAH group and at-risk groups versus others. cLonger disease duration at time of study in PAH group versus controls. dHigher proportion of patients with limited subtype in all groups except ILD. eHigher proportion of Scl-70-positive patients in ILD than other groups. fHigher proportion of centromere-positive patients in all groups compared with ILD.